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Abstract Introduction: We conducted a meta-analysis of the conflicting epidemiologic evidence on the asso-
ciation between midlife body mass index (BMI) and dementia.
Methods: We searched standard databases to identify prospective, population-based studies of
dementia risk by midlife underweight, overweight, and obesity. We performed random-effects
meta-analyses and meta-regressions of adjusted relative risk (RR) estimates and formally explored
between-study heterogeneity.
Results: We included 19 studies on 589,649 participants (2040 incident dementia cases) followed up
for up to 42 years. Midlife (age 35 to 65 years) obesity (BMI  30) (RR, 1.33; 95% confidence in-
terval [CI], 1.08–1.63), but not overweight (25 , BMI , 30) (RR, 1.07; 95% CI, 0.96–1.20), was
associated with dementia in late life. The association with midlife underweight (RR, 1.39; 95%
CI, 1.13–1.70) was potentially driven by residual confounding (P from meta-regression5 .004), se-
lection (P 5 .046), and information bias (P 5 .007).
Discussion: Obesity in midlife increases the risk of dementia. The association between underweight
and dementia remains controversial.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
Underweight, overweight, and obesity have been related
to all-cause mortality risk [1] and to various poorer health
outcomes [2], but their impact on the risk of dementia
remains debated [3]. Although global epidemic of over-
weight and obesity accrues, underweight endures in poorer
countries [4]. Therefore, the association of both obesity
and underweight with dementia has enormous public health
implications [5,6].
Excess body weight may increase dementia risk in late
life by contributing to the accumulation of brain lesions,
through vascular and dysmetabolic pathways [7,8].
However, because body weight tends to decline after
midlife, and neuropathology subtly progresses during the
long preclinical phase of dementia [9], issues of direction-
ality may arise with age and high body mass index (BMI)
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in late life may appear to be protective [10,11]. Any excess
risk is plausibly related to adiposity in midlife, when weight
gain is more pronounced [12], and associations with demen-
tia are least likely disease- and age-confounded. However,
whether midlife underweight relates to dementia risk re-
mains to be established.
Several systematic reviews and meta-analyses have been
published of epidemiologic studies that explored the rela-
tionship of standard BMI (body weight in kilograms divided
by height in meter square) definitions of underweight
(BMI , 18.5), overweight (25 , BMI , 30), and obesity
(BMI  30) in midlife with risk of dementia at old age
[13–17]. However, the evidence is rapidly expanding and
has become highly conflicting. Positive [18,19], null
[10,20,21], and inverse [22], associations between midlife
BMI and dementia risk have been reported, but whether
the study design and methods of primary studies introduced
bias and errors, which may explain the marked heterogeneity
of results across studies, is not known. A comprehensive and
updated systematic review and meta-analysis, coupled with
a formal exploration of sources of biases, is warranted. We
undertook a systematic review of epidemiologic studies as-
sessing the association of late-life dementia risk to midlife
underweight, overweight, and obesity, and we quantified
and formally explored the anticipated heterogeneity of re-
sults across studies.
2. Materials and methods
2.1. Search strategy and selection criteria
We used the Population, Intervention, Comparison, and
Outcome (PICO) framework [23] to search PubMed, Em-
base, Google Scholar, and the Cochrane library.We searched
for prospective, population-based studies published in En-
glish between January 1966 and October 2016 reporting
risk of dementia in old age (65 years or more) as a function
of exposure to underweight, overweight, or obesity in
midlife, defined as the period between early adulthood and
old age (35–65 years). To complement the electronic
searches, we hand-searched the bibliographies of relevant
publications and contacted experts in the field. Two indepen-
dent reviewers (E.A. and K.E.) examined titles and abstracts
using the following inclusion criteria: (1) cohort studies or
studies conducted using observational routinely collected
health data [24], with a 10 years or longer midlife to late-
life follow-ups; (2) measures of midlife underweight, over-
weight, and obesity modeled as independent variables in
the analysis, and (3) dementia diagnosis in late life (i.e.,
65 years or more). We excluded clinical, cross-sectional
and experimental studies, studies on trajectories of body
weight by dementia status [25], and duplicated publications.
Final decisions on inclusion were made by consensus. In the
meta-analysis, we included studies that reported risk esti-
mates for the association of midlife underweight, over-
weight, and obesity with a dementia diagnosis in late life.
2.2. Definitions
All included studies used BMI as a measure of total
adiposity, with the standard World Health Organization
BMI groups for underweight (BMI  18.5), normal weight
(18.5 , BMI , 25), overweight (25  BMI , 30), and
obesity (BMI  30 kg/m2); slightly different BMI cutoffs
of underweight (i.e., BMI, 20 kg/m2) were deemed appro-
priate for our analysis (Launer LJ, personal communication,
2015) [22]. We considered dementia diagnosis according to
standard diagnostic criteria, established using validated
multiphase diagnostic procedures, or based on death certifi-
cates, medical records, and hospital records. We contacted
the authors of primary studies to obtain further data and in-
formation when needed.
2.3. Data extraction
Two reviewers (E.A. and K.E.) used purposely designed
forms to independently abstract the following information:
study design, place, participants, outcome (e.g., dementia
diagnosis), and exposure’s ascertainment methods; covariates
and confounders (including lifestyle, sociodemographic,
health characteristics, and APOE polymorphisms); and the
statistical methods used. The main results of the most
adjusted models were abstracted and retained for the meta-
analysis.
2.4. Assessment of risk of bias
We assessed the susceptibility to bias of the included
studies combining the approaches recommended by the
Methods in Longitudinal Research on Dementia
(MELODEM) Initiative for dementia research [26] and by
Sanderson et al. for cohort studies [27]. Two independent re-
searchers (E.A. and K.E.) appraised the methodological qual-
ity (0 5 low, 1 5 adequate, and 2 5 optimal) across seven
criteria: (1) study design; (2) participants’ mean (or median)
age when body mass was measured; (3) underweight, over-
weight, and obesity ascertainment methods; (4) dementia
diagnostic criteria and ascertainment procedures; (5) adjust-
ment for potential confounders and relevant covariates [28];
(6) follow-up length between exposure assessment in midlife
and dementia diagnosis at older ages; and (7) study sample
attrition and proportion of participants at follow-up.
2.5. Statistical analysis
We combined the dementia risk estimates separately by
midlife underweight, overweight, and obesity compared
with normal BMI in random-effects models, pooling the
log-transformed relative risks (RRs), hazard ratios, and
odds ratios under the equivalence assumption for noncom-
mon events. If multiple results were reported for the same
cohort we used the later (i.e., with more years of follow-
up) [29,30] or the most comprehensive findings [31], we
combined risk estimates of men and women (except when
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the sex! BMI interaction terms in the primary study were
statistically significant [19]), and we conducted sensitivity
analyses stratified by sex. Because proneness to errors and
bias in population-based cohort studies and in studies con-
ducted using routinely collected health data differ substan-
tially [24], we stratified the main meta-analyses by study
design and compared the pooled dementia risk estimates
and heterogeneities accordingly.
We quantified heterogeneity using the standard low
(25%), moderate (50%), and high (75%) Higgins I2 values
cutoffs [32], and we investigated whether, and the extent
to which, any difference between studies in dementia risk es-
timates could be explained by their study design characteris-
tics in a set of meta-regression analyses.
In sensitivity analyses, we reran the meta-analyses for un-
derweight, overweight, and obesity by length of follow-up
time (the interval between ascertainment of midlife BMI
and dementia diagnosis at old age, equal, or more than vs.
less than 20 years), sex (studies conducted in men or women
only, or both), method of dementia diagnosis, and statistical
adjustment, and we formally explored the variation in
between-study variance (tau squared) across models [33].
Finally we investigated any suggestion of publication
bias and small-study effects by visual inspection of Funnel
plots, and we calculated asymmetry with modified Egger
regression using the Stata metabias routine [34,35]. For
illustrative purposes, we presented graphically a meta-
regression “bubble plot” by proneness to bias in the primary
studies. Further details about our methods are reported in
Appendix A. We used Stata 14 for all analyses (Stata Corp
LP, College Station, TX, USA).
3. Results
3.1. Included and excluded studies
Of the 512 records identified 426 were excluded after title
and abstract review. We examined the 86 potentially eligible
publications and two more retrieved from other sources as
full texts, 30 reports met the inclusion criteria. Of these,
11 were excluded because midlife BMI was predicted rather
than measured in midlife [14], was modeled as a continuous
variable [36], as a covariate in multivariate models [37,38],
or data were previously published [21,39–43]. We retained
512 records identified 
through database searching 
426 records excluded after title and abstract 
review
11 Excluded from the meta-analysis
7 Duplicated or with shorter follow-ups
1 BMI in midlife statistically estimated 
retrospectively
3 Results not reported by BMI categories 
(letters to authors not replied)
2 additional 
records identified 
through cross-
references
19 studies included in the 
meta-analysis 
30 studies included in the 
systematic review
86 full-text articles assessed 
58 Full-text articles excluded 
14 Editorials, overviews, reviews
4 Case-control or cross-sectional design
13 The main outcome was not dementia
22 Body mass not ascertained in midlife
5 Studies on weight change by dementia 
diagnosis
Fig. 1. Identification and selection of eligible studies.
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Table 1
Characteristics of included studies
Study acronym or
name (location)
Analytic sample
(% of female)
Mean follow-up,
years (SD)
Body mass ascertainment
procedures
Mean age, y
(SD or range)
when BMI was
ascertained
Dementia ascertainment (diagnostic
criteria), number of cases
Confounders included in the adjusted
model
Cohort studies
CHS (USA) [48] 2616 (59) 20.0 (N/A) Retrospectively self-reported
estimates, obtained in late life
50 (N/A) Multiphase consensus diagnosis
(clinical consensus), 461
Age, race, sex, education, APOE ε4
allele, late life: CRP, IL-6,
hypertension, cholesterol,
diabetes, CHD, ankle-arm index,
smoking, total kilocalories intake
PPSW (Sweden) [10] 651 (100) 32.0 (4.0) Standard, direct measures of body
height and weight (results on
overweight only)
47 (N/A) Clinical consensus (DSM-III-R), 161 Age, triglycerides, cholesterol, SBP,
age at menopause, education,
diabetes
Twin Registry
(Sweden) [30]
8534 (60) 30.0 (N/A) Self-reported estimates, obtained in
midlife
43 (15) Multiphase consensus diagnosis
(DSM-IV), 464
Age, sex, education, diabetes,
hypertension, stroke, and heart
disease
IIHD (Israel) [51] 1620 (0) 37.0 (6.0) Standardized direct measure of
weight and self-reported height
44 (N/A) Multiphase consensus diagnosis
(DSM-IV), 307
Age, diabetes, body height, SES
Twin Registry
(Finland) [52]
1601 (49) 22.6 (2.3) Self-reported estimates, obtained in
midlife (no results on
underweight)
51 (6.1) Automated algorithm (TELE; 16
cutoff), 650
Age, sex, education, APOE ε4 allele,
follow-up years
CAIDE
(Finland) [29]
1304 (61) 26.0 (5.1) Standardized direct measures 50 (N/A) Multiphase consensus diagnosis
(DSM-IV), 169
Age, sex, APOE, residence,
smoking, education, income,
diabetes, CVD, cerebrovascular
diseases, SBP, cholesterol
AGES (Island) [20] 3864 (57) 26.2 (4.9) Standard, direct measures of body
height and weight
50 (4.7) Multiphase consensus diagnosis
(DSM-IV), 190
Age, sex, follow-up years, APOE ε4
allele; midlife: education,
exercise, SBP, DBP, cholesterol;
late life: coronary artery calcium,
coronary artery disease,
hypertension, diabetes,
depression, alcohol and smoking
habits, and MRI brain measures
(white matter lesions and
intracranial volumes)
HAAS (USA)
(Launer LJ,
personal
communication,
2015)
3733 (0) 23.0 (4.0) Standard, direct measures of body
height and weight
59 (51–74) Multiphase consensus diagnosis
(DSM-III-R) 112
Age, education, stroke, hypertension,
diabetes, smoking, APOE ε4,
impaired physical function,
CES-D
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Rotterdam study (the
Netherlands) [47]
2085 (58) 15.0 (5.7) Standard, direct measures of body
height and weight
58 (1.4) Multiphase consensus diagnosis,
integrated with medical records
(DSM-III-R) 81
Age, sex, study cohort, systolic and
diastolic blood pressure, serum
cholesterol and HDL, use of
antihypertensive medication, use
of lipid-lowering medication,
diabetes mellitus, smoking (never,
former, current), level of
education, APOE genotype,
history of stroke
Studies that used, in part or entirely, observational routinely collected health data
MPPS (Sweden) [18] 7402 (0) 25.0 (7.0) Standard, direct measures of body
height and weight
52 (2) Hospital discharge or death
certificates (ICD-9; ICD-10) 254
Age, smoke, exercise, occupation;
midlife: diabetes, SBP, cholesterol
Kaiser Permanent
(USA) [19]
10,276 (55) 26.0 (9.0) Standard, direct measures of body
height and weight
43 (N/A) Outpatient medical records (ICD-9;
ICD-10) 713
Age, sex; midlife: education, race,
marital status, hypertension,
diabetes, cholesterol; and late-life
hypertension, stroke, diabetes,
IHD, cholesterol
MRMD and CSP
(Taiwan) [46]
785 (45) 15.0 (4.0) Standard, direct measures of body
height and weight
58 (N/A) Hospital records (DSM-IV, Chinese
version) 157
Self-reported cardiovascular
diseases and hypertension
ARIC (USA) [45] 11,151 (57) 12.8 (N/A) Standard, direct measures of body
height and weight
55 (N/A) Medical records (ICD-9) 203 Age, sex, race, study site, education,
occupational level, cognitive tests
at baseline, CVRFs, APOE ε4
allele
7 Countries
(Finland, Greece,
Italy, the Netherlands,
ex-Yugoslavia; Japan,
USA) [44]
10,211 (0) 25.3 (6.0) Standard, direct measures of body
height and weight
49 (40–59) Death certificates (ICD-8, code 290)
160
Age, study cohort, occupation, body
height, smoking; midlife
cholesterol, hypertension, FVC,
CVD
LSUHCSD (USA) [49] 44,660 (N/A) 12.9 (N/A) Midlife body height and weight
direct measures (no results on
underweight)
N/A (30–96) Revised medical records (DSM-IVor
ICD-9) 388
Age, sex, smoking, BP, cholesterol,
triglycerides; diabetes,
medications
HES (UK) [53] 241,146 (57) 15.0 (N/A) Admission for clinically diagnosed
obesity
50 (N/A) Hospital records or death certificates
(ICD-10) 321
Sex, place of residence
CPRD (UK) [22] 172,313 (55) 18.3 (2.2) Standard, direct measures of body
height and weight
55 (N/A) Clinical records or death certificates
(dementia subtypes diagnoses)
620
Age, sex, smoking, alcohol, statins,
antihypertensive use, diabetes,
myocardial infarction
Whitehall (UK) [50] 18,823 (0) 42.0 (N/A) Standard, direct measures of body
height and weight
55 (40–69) Death certificates (not specified) 283 Smoking habit and birth cohort
NCS and CONOR
(Norway) [31]
46,874 (51) 33.0 (N/A) Standard, direct measures of body
height and weight
43 (N/A) Death certificates (ICD-9; ICD-10)
711
Age, sex, study site (county); midlife
diabetes, physical inactivity,
smoking, SBP, DBP, cholesterol,
and education
Abbreviations: AGES, Age, Gene/Environment Susceptibility—Reykjavik Study (Reykjavik, Iceland); ARIC, atherosclerosis risk in communities; BMI, body mass index; CAIDE, cardiovascular risk factors
aging and dementia; CES-D, centers for epidemiologic studies depression scale; CHD, coronary heart disease; CHS, Cardiovascular Health Study (four US centers in MD, CA, PA, NC); CONOR, the cohort of
Norway; CPRD, Clinical Practice Research Datalink; CRP, C-reactive protein; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; DBP, diastolic blood pressure; DSM, Diagnostic and Statistical
Manual of Mental Disorders; FVC, forced vital capacity; HAAS, Honolulu-Asia Aging Study; HDL, high-density lipoproteins; HES, English National Hospital Episodes Statistics; ICD, International Statistical
Classification of Diseases and Related Health Problems; IHD, ischemic heart disease; IIHD, Israel Ischemic Heart Disease Project; IL-6, interleukin 6; LSUHCSD, Louisiana State University Hospital-Based
Longitudinal Study; MPPS, Multifactor Primary Prevention Study (Goteborg, Sweden); MRI, magnetic resonance imaging scan; MRMD and CSP, Multiple Risk Factors for Major Diseases and Cancer Screening
Program; NCS, The Norwegian Counties Study; PPSW, Prospective Population Study of Women in Sweden; SD, standard deviation; SBP, systolic blood pressure; SES, socioeconomic status; TELE, validated
telephone interview to detect cognitive impairment.
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19 studies for further analysis (Launer LJ, personal
communication, 2015) [10,18–20,22,29–31,44–53]. The
selection process is shown in Fig. 1 and reported in detail
in Appendix B and C.
Except for one multicenter study [44], one in Israel [51],
and one in Taiwan [46], studies were conducted in Northern
European countries including the UK [10,18,20,22,
29–31,49,50,52,53], or the USA (Launer LJ, personal
communication, 2015) [19,45,48,49]. Nine were purposely
designed population-based prospective cohort studies
(Launer LJ, personal communication, 2015)
[10,20,29,30,47,48,51,52], the other 10 were cohort studies
that used, to different extents, routinely collected health
data of exposure status (i.e., height and weight measured
during routine health checks or visits in midlife) or
outcome (i.e., dementia diagnosis from hospital records or
death certificates). The sample sizes ranged from 651 [10]
to 241,146 [53] for a total of 589,649 participants who
were followed up for up to 42 years from midlife to late
life [50]. There were 2040 incident dementia cases. Most
studies included men and women, one study included only
women [10], and five studies included only men (Launer
LJ, personal communication, 2015) [18,44,50,51]. In one
study, the first recorded clinical diagnosis of obesity was
extracted from hospital admission records [53], in three
studies body height and weight were self-reported in midlife
[30,52], or retrospectively in late life by dementia-free par-
ticipants [48]. Standard, direct measures of height and
weight were collected at baseline and used to calculate
BMI in the remaining studies. The participants’ ages at base-
line did not substantially differ, but the exact age ranges
could be determined only for six studies
[18,20,30,44,47,52]. All purposely designed cohort studies
adjudicated dementia diagnosis through clinical consensus
using validated, multiphase diagnostic procedures based
on various screening instruments followed by in-depth clin-
ical evaluation of screen positives. Dementia was ascer-
tained from death certificates in three cohort studies
[31,44,50], a combination of data extracted from medical
and hospital records [18,19,22,45,46,49,53], or a validated
algorithm of a telephone interview [52]. Dementia diag-
nostic criteria included the International Classification of
Diseases [54], the Diagnostic and Statistical Manual of
Mental Disorders (DSM, III-R and IV Edition) for all de-
mentias and dementia subtypes including Alzheimer’s dis-
ease (AD) and Vascular dementia (VaD) according to
standard criteria (Table 1) [55–57].
3.2. Risk of bias assessment
In four studies, age ranges of participants were wide and
a small proportion were likely older than 65 years at base-
line when midlife exposure status was assessed (Launer
LJ, personal communication, 2015) [49–51]. With two
exceptions, recall bias [48] and measurement errors or in-
consistencies [53] in exposure ascertainment were
unlikely. Outcome ascertainment was considered unbiased
in the eight studies that did not rely on death certificates or
hospital records (Launer LJ, personal communication,
2015) [10,20,29,30,47,51]. Adjustment for confounders
attenuated associations [29,48,52] and residual
confounding was probable in the five studies that did not
adjust for education [22,46,49,50,53]. The potential
confounding effect of stroke or cerebrovascular damage
was adjusted for in four studies only. Only few studies
had relatively short midlife to late life follow-up periods
(i.e., less than 20 years) [22,45–47,49,53]. Finally,
relevant proportions of participants were lost at the
follow-ups (i.e., up to 50%) in several studies, and poten-
tial bias because of attrition was addressed in only three
studies (Table 2) [10,20,22].
3.3. Meta-analyses and meta-regressions
There were 12 studies contributing data on midlife under-
weight (with the Kaiser Permanente study contributing two
data points, one for men and one for women). Compared
with healthy weight being underweight in midlife was asso-
ciated with 39% higher risk of dementia (RR, 1.39; 95%
confidence interval [CI], 1.13–1.70). Results were heteroge-
neous across studies (Higgins’ I2 5 42.1%; Cochrane Q
P 5 .055) and the increased risk for dementia was evident
in studies that relied on routinely collected health data
(RR, 1.73; 95% CI, 1.43–2.09), but not in the purposely de-
signed cohort studies (RR, 1.03; 95% CI, 0.85–1.25; Fig. 2);
P value for the interaction by study design in dementia risk
from meta-regression 5 .007. The meta-regression results
are presented in Appendix D.
Our random-effects meta-analysis indicated that being
overweight in midlife does not increase dementia risk (RR,
1.07; 95% CI, 0.96–1.20) (Fig. 3). Results were heteroge-
neous across cohort studies (I2 5 59.3%; P 5 .002), and
the effect modification by study design in dementia risk
was not significant (P 5 .434) (Appendix D).
The risk of dementia in those who were obese in midlife
was 33% higher (RR, 1.33; 95% CI, 1.08–1.634), and the
heterogeneity among studies was high (I2 5 77.1%;
P , .001). Among purposely designed cohort studies the
combined RR indicated a significant 47% higher risk of de-
mentia (RR, 1.47; 95% CI, 1.06–2.03). Results were mark-
edly heterogeneous between studies that made use of
routinely collected health data, including hospital records
and death certificates (I2 5 83.4%; P , .001), and the CIs
for the meta-analyzed dementia risk of midlife obesity
were wide and included one (RR, 1.23; 95% CI, 0.93–
1.64) (Fig. 4). There was no interaction by study design in
the association between midlife obesity and dementia
(P5 .826) (Appendix D). Fig. 5 displays the pooled adjusted
RRs of dementia (with 95% CI) by midlife underweight,
overweight, and obesity in all studies and by study design.
In the meta-regression, the association between midlife
underweight and dementia was significantly more likely
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found in studies more prone to selection bias (P5 .046) and
outcome ascertainment bias (P5 .007), with shorter follow-
up periods (P 5 .024) and greater participants’ attrition
(P 5 .007), and in which potential confounders were less
adequately controlled for (P5 .004) (Appendix D). Overall,
the RR of dementia bymidlife underweight decreased by 9%
(95% CI, 0.15–0.03; P5 .009) per unit increase in the over-
all score obtained combining the individual elements of our
critical appraisal tool. No such differences were found for
the associations of dementia with midlife overweight and
obesity when we accounted for the study design features
of the included studies (Appendix D and e-Fig. 2).
In the sensitivity analysis, there was no association be-
tween obesity and dementia in the six studies with shorter
follow-ups (i.e., less than 20 years) (RR, 1.18; 95% CI,
0.75–1.85), with less adequate adjustment (RR, 1.23; 95%
CI, 0.78–1.95), or those conducted in men only (RR, 1.28;
95% CI, 0.92–1.78) (Appendix E). Finally, on inspection
of the underweight funnel plot there was some suggestion
of asymmetry owing to missing positive studies for under-
weight and dementia based on small registry–derived data.
However, the formal asymmetry tests were not significant
for cohort (Egger’s test P value 5 .158) and in studies that
(also) used routinely collected health data (P 5 .266). We
noticed no asymmetry inspecting funnel plots, nor were
the formal asymmetry tests significant for overweight
(P . .208) and obesity (P . .482) (e-Fig. 2).
4. Discussion
We have conducted the most comprehensive systematic
review to date of longitudinal studies that have investigated
Table 2
Critical appraisal of included studies
Study name or acronym (location)
Sampling
procedure
Age at
baseline Exposure Outcome Adjustment
Follow-up
length
Losses at
follow-up
Cohort studies
CHS (USA) [48] 1 2 0 1 2 2 0
PPSW (Sweden) [10] 2 2 2 2 1 2 0
Twin Registry (Sweden) [30] 1 2 1 1 1 2 0
IIHD (Israel) [51] 2 1 2 1 1 2 0
Twin Registry (Finland) [52] 1 2 1 0 2 2 1
CAIDE (Finland) [29] 2 2 2 1 2 2 0
AGES (Island) [20] 2 2 2 1 2 2 2
HAAS (USA) (Launer LJ, personal communication, 2015) 2 0 2 1 2 2 2
Rotterdam study (the Netherlands) [47] 2 2 2 1 2 1 2
Studies that used, in part or entirely, observational routinely collected health data
MPPS (Sweden) [18] 1 2 2 0 1 2 2
Kaiser Permanente (USA) [19] 0 2 2 0 1 2 0
MRMD and CSP (Taiwan) [46] 0 2 2 0 0 0 0
ARIC (USA) [45] 0 2 2 0 2 0 2
7 Countries (Finland, Greece, Italy,
the Netherlands, ex-Yugoslavia; Japan, USA) [44]
1 2 2 0 1 2 2
LSUHCSD (USA) [49] 0 0 1 0 0 0 1
HES (UK) [53] 0 1 0 0 0 0 0
CPRD (UK) [22] 0 2 2 0 0 1 0
Whitehall (UK) [50] 2 0 2 0 0 2 0
NCS and CONOR (Norway) [31] 1 2 2 0 1 2 2
Abbreviations: AGES, Age, Gene/Environment Susceptibility—Reykjavik Study (Reykjavik, Iceland); ARIC, atherosclerosis risk in communities; CAIDE,
cardiovascular risk factors aging and dementia; CHS, Cardiovascular Health Study (four US centers in MD, CA, PA, NC); CONOR, The Cohort of Norway;
CPRD, Clinical Practice Research Datalink; HAAS, Honolulu-Asia Aging Study; HES, English National Hospital Episodes Statistics; IIHD, Israel Ischemic
Heart Disease Project; MPPS,Multifactor Primary Prevention Study (Goteborg, Sweden); MRMD and CSP, Multiple Risk Factors for Major Diseases and Can-
cer Screening Program; NCS, The Norwegian Counties Study; PPSW, Prospective Population Study of Women in Sweden.
NOTE. The critical appraisal criteria were defined as follows: Sampling: 05 inadequate (sampling is neither random nor systematic or does not guarantee the
representativeness of the target or frame population; twin studies are not considered representative of the general population); 15 adequate (systematic samples
drawn from community dwelling people); 2 5 optimal (random, representative samples of the target population based on electoral or other registries). Age at
baseline when BMI was measured: 0 5 inadequate (wide age ranges that may exceed 60 years); 1 5 adequate mean age for “midlife” (i.e., younger than
65 years) with wide ranges; 2 5 optimal: mean age limited to midlife and narrow age ranges. Exposure ascertainment: 0 5 inadequate (self-reported in late
life; nonstandard measures); 1 5 adequate (self-reported in midlife with validation of the procedure); 2 5 optimal (direct, standard measures in midlife).
Outcome ascertainment: 0 5 record-linkage (based on hospital records and death certificates); 1 5 clinical consensus diagnosis based on one or multiphase
design with screening; 2 5 one-phase designs or correctly applied multiphase designs (i.e., correct weighing back of those who screened negative in phase 1).
Adjustment: 05 inadequate (established potential confounders are missing, ex. education, sex, or age); 15 adequate (includes sociodemographic and health char-
acteristics); 25 complete (includes established potential confounders spanning sociodemographic, health characteristics, and APOE ε4 polymorphism). Follow-up
length (from midlife to late life): 0 5 less than 15 years; 1 5 more than 15 years for the all sample; 2 5 20 years or more than for the all sample. Proportion of
participants at follow-up: 05 less than 50%; 15 50.1% to 75%; 25 75.1% ormore (for registry-based study we considered the size of the study sample relative to
the database population). Overall quality score: this is obtained by summing up the scores of the eight quality criteria (range 0–14).
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the association between BMI in midlife and dementia risk.
Our results are based on 589,649 participants from up to
19 cohort studies and indicate that while being overweight
does not and being obese in midlife does confer a significant
increased risk of developing dementia at older ages. The re-
sults on the positive association between midlife under-
weight and dementia were inconsistent across studies.
Excess body weight in midlife may contribute to vascular
and neurodegenerative damage that underpins dementia
through vascular and dysmetabolic pathways [7], and directly
through cell-signaling proteins secreted by the adipose tissue
(e.g., leptin and adiponectin) [58]. Yet, mechanistic [59] and
epidemiologic evidence [60] suggests that dementia may
cause involuntary weight loss well before its clinical onset
[25,61], and low BMI may spuriously appear to be
detrimental for dementia (and high BMI protective) [62].
Therefore, focusing on midlife exposure was important to as-
sessing any differences in dementia risk, and our meta-
regressions suggest that the positive associations between
midlife underweight and dementia, which were reported
only in studies with follow-up periods less than 20 years
[22,45–47,49,53], may be disease-confounded and be ex-
plained, at least in part, by reverse causality.
Numerous factors, including depression, diabetes, hyper-
tension, and stroke may confound or mediate the association
between BMI and dementia [63], and the covariates in the
statistical models varied significantly between the included
studies. Although some factors may lay on the causal
pathway between obesity and dementia, residual confound-
ing may not be excluded and the lack of adjustment for
educational level [22,49,50,53], or type 2 diabetes [44–
46,50,52], which are strongly associated with both BMI
[64,65], and dementia [66,67], may have contributed to the
heterogeneity of findings.
Ascertainment procedures for dementia varied signifi-
cantly across studies from multiphase clinical consensus ap-
proaches (Launer LJ, personal communication, 2015)
[10,20,29,30,47,48,51] to routinely recorded health data
and death certificates [31,44,50]. The use of medical
records and administrative data presents both great
opportunities and challenges for dementia research
[24,26], because the use of these records as proxies for
dementia is hampered by underreporting and measurement
variability that may move the risk estimates toward the
null effect [68,69], and the diagnosis may be more likely
in obese subjects who tend to be sicker and make more
Overall  (I-squared = 42.1%, p = 0.055)
Swedish Twin Registry
Subtotal  (I-squared = 0.0%, p = 0.652)
Kaiser P women
HAAS
CHS
Multifactor study
MRMD/CSP Taiwan
Kaiser P men
UK-CPRD
Cohort studies that used health records
Whitehall
Subtotal  (I-squared = 0.0%, p = 0.717)
NCS & CONOR
AGES
Purposely designed cohort studies
ARIC
IIHD
Study
1.39 (1.13, 1.70)
0.79 (0.45, 1.38)
1.03 (0.85, 1.25)
1.45 (0.79, 2.67)
1.00 (0.80, 1.29)
1.20 (0.66, 2.17)
2.24 (1.02, 4.90)
1.95 (0.85, 4.50)
0.53 (0.07, 3.82)
2.08 (1.52, 2.86)
1.55 (0.97, 2.59)
1.73 (1.43, 2.09)
1.47 (1.01, 2.15)
1.40 (0.45, 4.39)
1.10 (0.10, 8.70)
1.43 (0.75, 2.71)
100.00
8.44
43.26
7.60
17.05
7.83
5.30
4.83
1.02
14.57
9.85
56.74
12.73
Weight
2.87
0.83
7.07
Relative risk (95% CI)  %
1.07 14.3
Fig. 2. Adjusted dementia relative risk by midlife underweight compared with normal body mass index.
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use of health services. This potential surveillance bias may
explain some of the most extreme positive results among
some of the studies included in our review [18,19,46,53].
A subtle length/survival bias may not be excluded either
[70]. Obesity increases mortality risk and may significantly
reduce survival in those with dementia because of poorer
health [1]. The use of routine data for dementia diagnosis
is biased by the severity of the disease [71]; therefore, the
shorter survival in those with dementia and obesity-related
comorbidities make them less likely to receive a diagnosis
before they die. Participants may be systematically misclas-
sified as disease-free, and competing risks model may not
counteract this misclassification error because the assump-
tion of nondifferential effects of exposure status on the ana-
lytic sample derivation may not hold [72].
Other sources of bias may exist. Underweight and obesity
are plausibly related to access and use of primary care ser-
vices, and they may influence data collection [24]. Lack of
clinical measures and missing values were more likely in
those with worse cardiovascular risk profiles who were
thus excluded from the analytic samples [20,30], and an
unknown number of people who were obese or
underweight in midlife and at higher risk of dementia
could have been systematically excluded because of
differential study enrollment, and differential attrition and
survival after enrollment. Both length and selection biases
could explain some recent findings on a seeming
protective effect of excess body weight in midlife for
dementia risk [22]. Nevertheless, across cohort studies there
was a significant and consistent 47% higher dementia risk
associated with obesity in midlife compared with normal
BMI, and the magnitude of the overall effect in the main
analysis (i.e., 33%) may be only a slight underestimate.
Some limitations areworth noting.We focused on “all de-
mentia” diagnosis as a proxy of the prevalence of the demen-
tia syndrome in general populations and did not explore
separately AD, VaD, and other dementia subtypes. However,
clear distinctions and differential diagnoses require a more
Overall (I-squared = 59.3%, p = 0.001)
NCS & CONOR
Cohort studies that used health records
Subtotal (I-squared = 65.4%, p = 0.002)
AGES
Kaiser P men
CHS
Study
Rotterdam
ARIC
MRMD/CSP Taiwan
Whitehall
Swedish Twin Registry
IIHD
CAIDE
7 Countries
Multifactor study
HAAS
Finnish Twins
UK-CPRD
Kaiser P women
LSUHCSD
PPSW
Purposely designed cohort studies
Subtotal (I-squared = 55.4%, p = 0.022)
1.07 (0.96, 1.20)
1.01 (0.86, 1.19)
1.09 (0.92, 1.28)
1.22 (0.92, 1.63)
1.16 (0.91, 1.46)
1.01 (0.83, 1.35)
0.70 (0.42, 1.17)
0.70 (0.30, 1.50)
1.42 (0.92, 2.19)
0.98 (0.77, 1.26)
1.71 (1.30, 2.25)
Relative risk (95% CI)
1.05 (0.79, 1.40)
1.04 (0.58, 1.87)
0.88 (0.62, 1.26)
1.69 (1.00, 2.85)
1.05 (0.84, 1.31)
0.88 (0.63, 1.23)
0.80 (0.66, 0.97)
1.55 (1.22, 1.97)
1.13 (0.47, 2.70)
0.72 (0.40, 1.28)
1.06 (0.90, 1.25)
100.00
8.45
52.79
6.18
7.07
6.94
3.30
1.65
4.08
6.89
6.39
Weight %
6.18
2.73
5.10
3.20
7.34
5.39
7.89
7.01
1.45
2.76
47.21
1.3 3.33
Fig. 3. Adjusted dementia relative risk by midlife overweight compared with normal body mass index.
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detailed clinical evaluation over time, which is not usually
possible in epidemiologic studies. We used standard World
Health Organization categories of midlife BMI in our anal-
ysis. BMI is a surrogate measure of global adiposity and has
limitations, although particularly in older adults [73]. How-
ever, BMI can accurately distinguish between categories of
percentage of body fat, it performs similar to other anthropo-
metric measures in the population (including waist circum-
ference) [74], and is associated with mortality greater than
and less than the conventional normal range of 22.5 to
25 kg/m2 [1]. Thus, we integrated our searches contacting
several authors, retrieved, and included twice the number
of reports compared with previous reviews [13,15], and
gathered missing information to harmonize results of
primary studies on dementia risk by midlife BMI
categories are all major strengths of our review along with
the formal exploration of the sources of heterogeneity of
results.
Although comparisons are not straightforward, because
among the 19 studies that met our inclusion criteria 12
were published only recently (Launer LJ, personal commu-
nication, 2015) [20,22,29–31,47,49–53], our findings on
midlife obesity are in line with those of previous reviews
[13,14]. Namely, a meta-analysis of three studies found a
64% significantly higher all-dementia risk associated with
Fig. 4. Adjusted dementia relative risk by midlife obesity compared with normal body mass index.
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midlife obesity compared with healthy body weight [13],
and a similar magnitude (i.e., 60%) was found combining
the results of five cohort studies for Alzheimer’s disease
risk by others [75]. An increased risk of dementia by midlife
overweight was found in a previous meta-analysis [13] of
three cohort studies [18,19,48]. Our results are based on
14 additional data points, which became available only in
recent years, and indicate that there is no association
between midlife overweight and any dementia, which is
consistent with the findings of other systematic reviews
[15–17]. As outlined earlier, weight loss in people with
dementia begins decades before clinical onset and accrues
gradually through stages of dementia [59,76,77], such that
midlife to late-life trajectories of body weight have been
found to vary by dementia status at older ages
[25,61,78,79]. However, the biological plausibility of the
link between underweight in midlife and risk of dementia
in late life remains a matter of debate, and the scanty
epidemiologic evidence limits comparisons with our
results. Evidence is urgently needed particularly from low
and middle income countries, where prevalence of
underweight is highest.
Our main findings are consistent with the hypothesis of a
causal link between obesity and dementia [8]. Because the
prevalence of obesity exceeded 10% in most countries in
2014 [4], and the steepest increases in obesity prevalences
are occurring in those regions where populations are also
more rapidly aging [80], the detrimental contribution of
obesity to the catastrophic projections of dementia preva-
lence in the coming years [81] seems destined to accrue
heftily, particularly in low and middle income countries
[6]. In addition, because dementia risk may further increase
with longer duration and accumulation of exposure to high
adiposity throughout the life course [7], there is an urgent
need to investigate the association of obesity in childhood
and throughout adulthood with dementia in late life. Future
directions in research could also include the use of
individual-participant data meta-analysis [1] and Mende-
lian randomization designs (that exploit gene polymor-
phisms of known function to examine the causal effect of
a modifiable exposure on disease in nonexperimental
studies) [82], which may have the potential to advance
significantly our knowledge on modifiable risk and protec-
tive factors of dementia. Mechanistic studies are also war-
ranted to identify the pathways through which obesity
(and underweight) may increase dementia risk, and transla-
tional research should investigate whether weight loss in
midlife can influence metabolic flexibility and vascular
reactivity through long-term positive effects on intermedi-
ate metabolism, endothelial function, inflammation, and
oxidative stress (Box 1). Nonetheless, we maintain that
the lack of any such evidence should not delay public health
actions on a global scale aimed at reducing the population
exposure to interrelated vascular risk factors (including
obesity, diabetes, high blood pressure, and physical inac-
tivity), and that these actions should target young, middle
aged, and older people alike to reduce dementia risk and
to attain better and longer lasting health results for individ-
uals, and greater benefits to societies at large.
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Box 1
Future directions, a roadmap to further explore the link of adiposity and dementia
1. Life course observational epidemiologic research aimed at providing clues to the etiology of dementia, building and
testing theoretical models of causal pathways to dementia in late life that account for the timing and duration of expo-
sure to high and low adiposity throughout the life course, and for the concomitant potential modifying or mediating
effect of other exposures.
2. Basic science research to explore biologically plausible mechanisms and pathways through which high (and low)
adiposity may modulate the risk of dementia, its biological underpinnings and its clinical expression, at both the in-
duction and latency phase of the disease.
3. Clinical-translational and implementation research aimed at designing complex interventions for brain and cognitive
health promotion, and prevention and treatment of impairment, in patients and target populations, testing their efficacy
and effectiveness, and the scalability of their provision through health and social care services.
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RESEARCH IN CONTEXT
1. Systematic review: We retrieved prospective,
population-based studies of midlife body mass in-
dex and dementia risk using PubMed and contacted
authors to maximize the comprehensiveness of the
analysis. The evidence is highly conflicting and has
rapidly expanded in recent years.
2. Interpretation: Our findings resolve the current un-
certainty about the detrimental role of obesity in
midlife for dementia risk at old ages and question
the potential harm of low body mass index, thus sug-
gesting that the obesity paradox does not extend to
dementia.
3. Future directions: Future studies should focus on
whether sensitive periods and/or cumulative effects
of exposure to obesity throughout the life course exist;
mechanistic and observational studies are needed to
explore the potential role of underweight in midlife
in dementia riskmodulation. Finally, the effectiveness
of public health actions aimed at tackling the global
obesity epidemic in lessening the global burden of de-
mentia should be formally investigated.
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